Earnings Forecast Research on Aurinia Pharmaceuticals Inc (AUPH)

Aurinia Pharmaceuticals Inc has received $-0.1 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.11 while the top line estimate is $-0.1 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 35.94%.

Aurinia Pharmaceuticals Inc results fell short with a surprise EPS of -35.71% or $-0.05. The Actual EPS was $-0.19 compared to the Estimated EPS of $-0.14 during its most recent quarterly earnings.

In the last quarter, Aurinia Pharmaceuticals Inc reported Annual Earnings of $-0.19. Based on the filings, last years Annual Earnings was, $-0.68. In the last Quarter, AUPH reported a surprise Earnings per Share of -35.71% . The consensus estimate for current quarter is $-0.1 and for the current fiscal year, the estimate is $-0.51. For the Next fiscal year, the estimate is $-0.44 based on the consensus.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.12 points or 3.75% at $3.08 with 1,393,163 shares getting traded. Post opening the session at $3.24, the shares hit an intraday low of $3.06 and an intraday high of $3.24 and the price was in this range throughout the day. The company has a market cap of $159 million and the number of outstanding shares has been calculated to be 51,571,775 shares. The 52-week high of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is $5.6899 and the 52-week low is $1.7375.

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The companys lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Aurinia

Share this post

Leave a Reply